Intuitive Surgical

Intuitive Surgical reported third-quarter revenue growth of 22% and an increase in procedures of about 15%. Analysts see tailwinds from the new da Vinci 5 and sustained demand in parts of Europe; Baird raised its price target to $550. The stock shows relative strength, is poised to break above $458, and market experts attribute roughly 25% more upside to the shares. » Mais em deraktionaer.de

Intuitive Surgical beat revenue and earnings expectations in the third quarter, pushing the share price back up after a temporary pullback of around ten percent. The stock outperformed the market and briefly reached its highest level since May, sustainably breaking above the 200-day moving average. Analysts view the pullback as a buying opportunity despite concerns about comparison effects and growth worries in the U.S. » Mais em deraktionaer.de

Intuitive Surgical reported third-quarter revenue up 22% to $3.05 billion and adjusted earnings per share of $3.00, both well above analysts’ estimates. Procedures using surgical robots rose 15% and the installed base of Da‑Vinci systems topped 12,000 units for the first time. Despite the strong results, the stock sank by just over ten percent at one point after the company said it will pay a $450 million settlement. Intuitive holds $6.8 billion in cash and announced share buybacks of about $2.94 billion. » Mais em deraktionaer.de

Intuitive Surgical will report third-quarter results on Tuesday after the US market close. Analysts expect revenue of $2.91 billion and adjusted earnings per share of $2.65. Key for the stock is whether management classifies the slowed growth in Da Vinci procedures in the US as temporary and raises the full-year guidance; the shares are currently about 30% below their 52-week high and just under the 200-day moving average. Competitive pressure from Stryker and CMR Surgical is cited as an additional risk factor. » Mais em deraktionaer.de

At the Wells‑Fargo conference, Intuitive Surgical reported a slowdown in growth of U.S. procedure volumes but reaffirmed its guidance for global procedure growth of 13.5–15.5% and expects results near the midpoint. The company reported robust revenue, margin and free‑cash‑flow growth in the first half and highlighted support from system upgrades, the launch of the da Vinci 5, expansion into ambulatory surgery centers, and AI and software offerings. Competitive pressure from new market entrants and challenges in China, as well as a decline in bariatric procedures, are cited as headwinds; the operating margin target remains 35–40% and significant share buybacks have been carried out. » Mais em de.investing.com